Challenges for Corporate CEOs in 2011
2010 was a trying year for every business. Even with the recent glimmers of economic improvement, 2011 will be no less challenging. I was recently…
Posted by
2010 was a trying year for every business. Even with the recent glimmers of economic improvement, 2011 will be no less challenging. I was recently…
Posted by
Earlier this quarter, we announced that partner companies Clarient (Nasdaq: CLRT) and Avid Radiopharmaceuticals had signed definitive agreements to be acquired by GE Healthcare and…
Posted by
In this morning’s Wall Street Journal, Justin Lahart wrote an article titled “Companies Cling to Cash.” Justin reports that there is an increasing number of…
Posted by
A few months ago, I wrote about a partnership that means a great deal to me and to my colleagues at Safeguard Scientifics — the…
Posted by
For the second time in as many weeks, I am pleased to announce that a major player in the pharmaceutical industry has recognized the value…
Posted by
Earlier today in our third quarter results conference call, we announced that our aggregate partner company revenue increased 73 percent in Q3, and that for…
Posted by
REMINDER: Our third quarter results will be issued tomorrow morning at 6am EDT. Our webcast and conference call will be held at 9am EDT. Here’s…
Posted by
Safeguard Scientifics’ partner company NuPathe submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA). The NDA was filed for ZelrixTM,…
Posted by
At Safeguard Scientifics, our strategy is to provide growth capital for entrepreneurial and innovative life sciences and technology companies, build value in those companies and…
Posted by